Biomarkers and Surrogate Endpoints

With more biologic medicines becoming available to treat a broad range of health conditions, it’s important to understand how these complex, “large-molecule” medicines differ from small-molecule medicines people may be more familiar with.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.